Terms: = Gastric cancer AND BCL2, Bcl-2, 596, ENSG00000171791 AND Clinical Outcome
10 results:
1. Frequency Of Double Expressor Lymphoma In A Tertiary Care Hospital.
Hassan M; Khattak MT; Qamar MA; Javed S; Saeed SU
J Ayub Med Coll Abbottabad; 2021; 33(1):44-48. PubMed ID: 33774953
[TBL] [Abstract] [Full Text] [Related]
2. Solitary fibrous tumor of the anterior abdominal wall. A case report and review of the literature.
Testa DC; Selvaggi F; Andreano T; Mazzola L; Cortellese R
Ann Ital Chir; 2019 Jun; 8():. PubMed ID: 31366738
[TBL] [Abstract] [Full Text] [Related]
3. [Clinicopathological characteristics and prognostic analysis of 92 cases with primary gastrointestinal diffuse large B-cell lymphoma].
Feng J; Wan W; Wan W; Wang J; Jing H; Wang J; Zhao W; Liu Y; Ke X
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):288-94. PubMed ID: 24759013
[TBL] [Abstract] [Full Text] [Related]
4. Loss of bcl2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma.
Xu JD; Furuya T; Cao XX; Liu XL; Li QQ; Wang WJ; Xu JW; Xu ZD; Sasaki K; Liu XP
Histopathology; 2010 Dec; 57(6):814-24. PubMed ID: 21166696
[TBL] [Abstract] [Full Text] [Related]
5. Reduction of TIP30 correlates with poor prognosis of gastric cancer patients and its restoration drastically inhibits tumor growth and metastasis.
Li X; Zhang Y; Cao S; Chen X; Lu Y; Jin H; Sun S; Chen B; Liu J; Ding J; Wu K; Fan D
Int J Cancer; 2009 Feb; 124(3):713-21. PubMed ID: 18972434
[TBL] [Abstract] [Full Text] [Related]
6. [Expression of p53 and BCI-2 as prognostic markers and for anatomical location in gastrointestinal stromal tumors (GIST). Clinico-pathological and immunohistochemistry study of 19 cases].
Martínez-Consuegra N; Baquera-Heredia J; de León-Bojorge B; Padilla-Rodríguez A; Hidalgo CO
Rev Gastroenterol Mex; 2006; 71(3):269-78. PubMed ID: 17140048
[TBL] [Abstract] [Full Text] [Related]
7. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
Nagashima F; Boku N; Ohtsu A; Yoshida S; Hasebe T; Ochiai A; Sakata Y; Saito H; Miyata Y; Hyodo I; Ando M
Jpn J Clin Oncol; 2005 Dec; 35(12):714-9. PubMed ID: 16303791
[TBL] [Abstract] [Full Text] [Related]
8. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathologic and immunohistochemical study of surgically treated primary gastric MALT lymphoma.
Insabato L; Di Vizio D; Tornillo L; D'Armiento FP; Siciliano A; Milo M; Palmieri G; Pettinato G; Terracciano LM
J Surg Oncol; 2003 Jun; 83(2):106-11. PubMed ID: 12772204
[TBL] [Abstract] [Full Text] [Related]
10. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
Boku N; Chin K; Hosokawa K; Ohtsu A; Tajiri H; Yoshida S; Yamao T; Kondo H; Shirao K; Shimada Y; Saito D; Hasebe T; Mukai K; Seki S; Saito H; Johnston PG
Clin Cancer Res; 1998 Jun; 4(6):1469-74. PubMed ID: 9626464
[TBL] [Abstract] [Full Text] [Related]
